nv-5138
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 6, 2018 (NCT03606395)
Timeline
Indications
Mechanism of action
Mammalian target of Rapamycin (mTORC1) activator
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C[C@H](N)C(=O)O)C(F)F- Mol. weight
- 181.18 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650303 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226661 | Phase 2 | Jan 1, 2026 | Supernus Pharmaceuticals |
| NCT06235905 | Phase 2 | Feb 15, 2024 | Navitor Pharmaceuticals, Inc., Supernus Pharmaceuticals |
| NCT05066672 | Phase 2 | Dec 31, 2021 | Antengene Corporation, Navitor Pharmaceuticals, Inc., Supernus Pharmaceuticals |
| NCT05152680 | Phase 1 | Nov 11, 2021 | Navitor Pharmaceuticals, Inc., Supernus Pharmaceuticals |
| NCT05384977 | Phase 1 | Nov 11, 2021 | Supernus Pharmaceuticals |
| NCT03606395 | Phase 1 | Jun 6, 2018 | Navitor Pharmaceuticals, Inc., St. Louis Clinical Trials, LC |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals | For profit | 5 | 2 | 2 | 2021 |
| Navitor Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2018 |
| Antengene Corporation | For profit | 1 | 0 | 1 | 2021 |
| St. Louis Clinical Trials, LC | For profit | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1